Wai Chun Bio-Technology Limited (abbrev. Wai Chun Biotec) reported a change in share capital following the conversion of its outstanding convertible bonds.

On 7 July 2026 the company allotted 16.67 million new ordinary shares at HK $0.01 each upon conversion of convertible bonds with an aggregate principal amount of HK $1.00 million. The issuance lifted the company’s outstanding share count to 384.31 million shares from 367.64 million shares, representing a 4.53% expansion.

No treasury shares were outstanding before or after the transaction, and the disclosure confirms that no share repurchases or on-market disposals of treasury shares occurred during the period.

The board affirmed that the share issue complied with all applicable listing rules and regulatory requirements, and that all proceeds from the conversion have been duly received.